Catalyst
Slingshot members are tracking this event:
Data from the ongoing Phase 1 study of ALN-AS1 for the treatment of acute hepatic porphyrias, including initial data in patients that experience recurring porphyria attacks - in late 2016.
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALNY | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 07, 2016
Occurred Source:
http://investors.alnylam.com/releasedetail.cfm?ReleaseID=988112
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1, Aln-as1, Acute Hepatic Porphyrias, Recurring Porphyria Attacks
